The 2024 SABCS® will explore the hype and reality of AI during two sessions, including a discussion on revolutionizing diagnosis and discovery, moderated by Frederick Howard, MD.
David S. Miller, MD, discusses key efficacy, safety, and quality-adjusted survival data with selinexor in TP53 wild-type endometrial cancer.
A panel discussed on RCC and the differentiation in the identification and treatment of clear and non-clear cell RCC.
IGV-001, an autologous cell immunotherapy, demonstrated an acceptable safety profile in patients with newly diagnosed glioblastoma.
A biologics license application was submitted to the FDA seeking the approval of RP1 plus nivolumab for patients with PD-1 inhibitor–exposed melanoma.
The NCI Cancer Research Data Commons has launched the Clinical and Translational Data Commons, a dedicated resource for NCI-funded clinical and translational data. Learn more…
At OHSU Knight Cancer Institute, patients are front of mind in drive toward cancer early detection, interventions.
In growing cell populations such as cancer, mutations can serve as markers that allow tracking the past evolution from current samples. The genomic analysis of…
To improve the quality of medical care in developing countries, ASH has partnered with Health Volunteers Overseas (HVO), a nonprofit organization dedicated to improving global…
PURPOSETo investigate whether the addition of hyperthermic intraperitoneal chemotherapy (HIPEC) to secondary cytoreductive surgery (SCS) without neoadjuvant chemotherapy has a benefit on progression-free survival (PFS),…
Lu Chen, PhD, an Assistant Professor in the Nuclear Dynamics and Cancer Research Program has received a grant from the NIH to further investigate the…
